精密生物科学在香港获得了扩大基因编辑乙型肝炎试验的核准。 Precision BioSciences gains approval to expand gene editing hepatitis B trial in Hong Kong.

精密生物科学已获得香港批准,扩大第一阶段临床试验,称为ELINMINATE-B,目的是利用新的基因编辑疗法治疗慢性乙型肝炎。 Precision BioSciences has received approval in Hong Kong to expand its Phase 1 clinical trial, called ELIMINATE-B, which aims to treat chronic hepatitis B using a new gene editing therapy. 该审判的名称是PBGENE-HBV,现在准备让更多在香港的参与者参加,以进一步测试治疗的安全和有效性。 The trial, named PBGENE-HBV, is now set to include more participants in Hong Kong to further test the safety and effectiveness of the treatment.